https://www.**promotion blocked**/investing/2019/06/10/is-axovant-gene-therapi...

https://www.**promotion blocked**/investing/2019/06/10/is-axovant-gene-therapies-a-buy.aspx

””Unfortunately, the sub-$150 million business has been left out of the field's rise, suggesting the collective wisdom of the biopharma industry isn't interested in the company's approach. While there is always a handful of overlooked small-cap stocks that prove everyone wrong (Benitec) recent events and pipeline updates don't provide much reason to think Axovant Gene Therapies has a coherent strategy in place that would even provide the chance to wear that label. For now, this gene therapy stock is simply too risky for your portfolio.””


Well time is revealing that the termination of the agreement with Axovant is looking increasingly good for Benitec and increasingly bad for Axovant. While Axovant is shunned by investors and its shareprice plunging and not impressing the wider market with its limited pipeline, Benitec is poised to announce a streamlined delivery system for OPMD and multiple new and exciting proprietary programs that will excite the market.